论文部分内容阅读
目的研究长效钙拮抗剂对高血压(HD)的治疗方法及其疗效。方法选择2009年7月至2012年4月,在我院治疗过的64例HD病人,随机将其分为两组,一组接一般治疗(对照组),另一组在常规治疗基础上服用长效钙拮抗剂(治疗组),每组均为32例。治疗后检测两组收缩压(SBP)和舒张压(DBP)变化,观察其对HD的疗效以及不良反应等。结果 CA治疗组有效和总有效例数及比例均显著高于对照组(P<0.05),而无效例数和无效率显著低于对照组(P<0.01);SBP和DBP分别为(18.11±1.45)kPa和(13.08±1.24)kPa,与服用CA前比较,SBP和DBP显著降低(P<0.05);同时,与一般治疗组治疗后SBP和DBP比较,两组间差异达到显著水平(P<0.05);不良反应率仅为3.125%,CA治疗组不良反应显著少于对照组(P<0.05)。结论长效钙拮抗剂能够显著降低SBP和DBP,提高对HD的临床疗效,且不良反应,对HD疗效确切,可在临床上推广应用。
Objective To study the treatment of hypertension (HD) with long-acting calcium antagonists and its efficacy. Methods Sixty-four patients with HD who were treated in our hospital from July 2009 to April 2012 were randomly divided into two groups: one group received general treatment (control group) and the other group received conventional treatment Long-acting calcium antagonists (treatment group), each group was 32 cases. The changes of systolic blood pressure (SBP) and diastolic blood pressure (DBP) in both groups were detected after treatment, and the curative effect and side effects on HD were observed. Results The number of effective and total effective cases and the proportion of CA in treatment group were significantly higher than those in control group (P <0.05), while the number of ineffective cases and inefficacy was significantly lower than that in control group (P <0.01). The SBP and DBP were (18.11 ± 1.45 kPa and 13.08 ± 1.24 kPa, respectively, SBP and DBP decreased significantly compared with those before CA administration (P <0.05). Meanwhile, compared with SBP and DBP in general treatment group, the difference was significant (P <0.05). The rate of adverse reactions was only 3.125%. The adverse reactions in CA group were significantly less than those in control group (P <0.05). Conclusion Long-acting calcium antagonists can significantly reduce the SBP and DBP, improve the clinical efficacy of HD, and adverse reactions, the exact effect on HD, which can be widely applied in clinic.